Lung Cancer | Specialty

Upfront Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy for NSCLC

July 13th 2017

The Ever-Evolving Treatment Paradigm for NSCLC

July 13th 2017

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

July 13th 2017

Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

Expert Stresses True Definition of Palliative Care for Patients With Lung Cancer

July 6th 2017

Rachel Dibble, NP, discusses the importance of palliative care at the start of diagnosis for patients with non-small cell lung cancer and explained its differences from end-of-life care.

Dr. Garon on Future of Immunotherapy in NSCLC

July 6th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the future of immunotherapy in the paradigm of non–small cell lung cancer (NSCLC).

Expert Discusses Dramatic Impact of Immunotherapy on NSCLC Paradigm

July 6th 2017

Melissa Johnson, MD, discusses the impact of immunotherapy for patients with non-small cell lung cancer—those with both high and low levels of PD-L1 expression—and how the treatment and the role of PD-L1 will continue to progress in the coming years.

Blood-Based Assays Are Addition, But Not Replacement for Lung Tissue Biopsies

July 5th 2017

Leora Horn, MD, MSc, discusses the utility of blood-based biomarkers, how they have transformed treatment approaches for patients with non-small cell lung cancer, and the ongoing work currently being done with them.

EU Approves Frontline Ceritinib for ALK+ NSCLC

June 29th 2017

The European Union has approved the use of ceritinib for the first-line treatment of patients with ALK-positive advanced non­–small cell lung cancer.

A Comprehensive Review of Hemibody Irradiation for Patients with Bone Metastases

June 28th 2017

A comprehensive review was initiated on hemibody irradiation for patients with solid tumors with an emphasis on bone metastases to determine the efficacy and the toxicity of this treatment.

Clinical Data Can Mislead Without Meaningful Analysis

June 27th 2017

CMS has put so much emphasis on reported data that it is now paramount for oncology practices to understand how data should be sifted and interpreted to arrive at meaningful conclusions.

Future Directions for Treatment of Lung Adenocarcinoma

June 23rd 2017

Evolving Approaches for Treating ALK-Positive NSCLC

June 23rd 2017

Emerging Options for Treatment of EGFR-Positive NSCLC

June 23rd 2017

Treatment of Metastatic EGFR-Positive NSCLC

June 23rd 2017

The Potential for Adjuvant Immunotherapy for NSCLC

June 23rd 2017

Novel Trials of Immunotherapy Combinations for NSCLC

June 23rd 2017

Late-Stage Trials: Immunotherapy Combinations for NSCLC

June 23rd 2017

The Current Role for Antiangiogenic Therapy for NSCLC

June 23rd 2017